Bristol Myers Squibb’s latest facility in Moreton, Wirral marks a significant step in its construction process. The complex, reaching its highest structural point, is poised to become a hub for pharmaceutical advancements.
Spanning 37,000 square feet, this facility will feature open-plan offices and state-of-the-art laboratories, accommodating up to 200 employees. It is designed to enhance the site’s innovation capabilities while achieving BREEAM ‘outstanding’ accreditation for sustainability.
The construction of this advanced drug development site in Moreton is proceeding under the expertise of Eric Wright Construction. With the structure now at its peak, important components such as roof installations are actively underway. This milestone not only signifies physical progress but also highlights the strategic importance of the site within the pharmaceutical landscape, aiming to reinforce Bristol Myers Squibb’s commitment to innovative drug development.
The inclusion of expansive glazing panels is another noteworthy feature, maximising natural light and reducing reliance on artificial lighting. Inside, the flexible spaces are designed to foster collaboration and adaptability, supporting a dynamic work environment.
The facility is not just an infrastructure project; it is a strategic asset. It will provide cutting-edge laboratory and office spaces, ensuring Bristol Myers Squibb remains at the forefront of pharmaceutical innovation and employee engagement.
By establishing a major site in Moreton, Bristol Myers Squibb demonstrates its commitment to the north-west’s economic growth, enhancing local capabilities and attracting further investment into the area.
Through this development, Bristol Myers Squibb not only strengthens its operational base in the UK but also cements its role as a leader in sustainable and innovative pharmaceutical research.
By aligning its new facility with green building standards, Bristol Myers Squibb sets a benchmark for future industry developments, illustrating its commitment to environmental stewardship in all phases of the project.
The achievement of this construction milestone signifies a pivotal advancement for Bristol Myers Squibb in the UK. The facility is expected to bolster local employment, enhance the company’s research capabilities, and set a standard for sustainable development in the pharmaceutical industry.
Bristol Myers Squibb’s new Moreton facility marks an impressive milestone, with the project progressing as planned towards an estimated completion in May 2025. With its focus on innovation and sustainability, the centre will undoubtedly play a crucial role in the company’s future research efforts while supporting local economic development.
